NCT05065658

Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients

Posaconazole for the Prevention of COVID-19 Associated Pulmonary Aspergillosis in Critically-Ill Patients: A European Multicenter Case-Control Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 249 (actual)
• Sponsor: Medical University of Graz · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

COVID-19 associated pulmonary aspergillosis (CAPA) is considered a potentially life-threatening infection in critically ill COVID (Corona Virus disease)-19 patients. This study will investigate the efficacy of mold-active prophylaxis with posaconazole for patients with severe SARS (severe acute respiratory syndrome)-CoV-2 infection admitted to the ICU (intensive care unit) in a multi-center case-control study in Europe.

Conditions

• COVID-19 Respiratory Infection
• Aspergillosis

Interventions

Type	Name	Description
DRUG	Posaconazole	Intravenous posaconazole prophylaxis

Timeline

• Start date: 2020-03-01
• Primary completion: 2023-08-23
• Completion: 2023-08-23
• First posted: 2021-10-04
• Last updated: 2025-02-17
• Results posted: 2025-02-17

Locations

3 sites across 3 countries: Austria, France, Italy